πŸ‡ΊπŸ‡Έ

US SEC Filing Intelligence

Β· daily

US Executive Officer Management Changes SEC β€” March 31, 2026

Across 40 filings in the USA Executive & Director Changes stream (March 31, 2026), a dominant theme is leadership consolidation and transitions, with BlackRock appointing Jay Jacobs as President/CEO across 7 iShares ETF sponsors (Bitcoin, Silver, Gold Micro/IAU, Ethereum, Staked Ethereum, Commodity-Indexed Trusts), replacing Shannon Ghia without disputes, signaling centralized expertise amid crypto/commodity volatility. Positive appointments dominate (e.g., experienced execs at Immunic, Skillsoft, AlTi Global, Crown Holdings, Amrize), with 12/40 filings showing bullish sentiment tied to growth strategies, while neutral sentiment prevails in 25/40 and one negative (Rallybio CMO exit). Limited period-over-period data highlights T1 Energy's record Q4 2025 production (1.13 GW, +YoY sales $358.5M) and improved net loss (-$190M vs -$367M Q4 2024), maintaining 2026 guidance (3.1-4.2 GW); other trends include AlTi's $93B AUM and Amrize's $11.8B 2025 revenue. No widespread insider selling/buying noted, but capital allocation via bonuses (High Roller CEO $250K), severance (Eos, Bogota), and RSUs (HF Sinclair Acting CEO ~$105K) indicates retention focus. Portfolio implications: Stability in finance/biotech (e.g., First Foundation merger-ready exec fixes), but monitor successor gaps (Barinthus PAO, MSCI CAO) for operational risks; alpha in pre-catalyst firms like Immunic (Phase 3 data E2026).

40 high priority 40 total filings
Β· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings β€” March 31, 2026

Two biotech/pharma companies, Lipella Pharmaceuticals Inc. and IO Biotech, Inc., filed for bankruptcy within two days (March 30-31, 2026), signaling acute distress in the emerging growth biotech sector amid funding challenges and operational failures. Both filings carry maximal materiality (10/10) with uniformly negative sentiment, warning shareholders of highly speculative trading, substantial total loss risks, and no expected recoveries. No positive period-over-period trends evident; instead, implied severe deterioration led to Chapter 11 (Lipella, reorganization) and Chapter 7 (IO Biotech, liquidation) proceedings, with IO Biotech ceasing all operations, terminating staff/leadership, and defaulting on a €22.5M EIB loan. Key market implication: Nasdaq-listed IOBT and Lipella shares decouple from fundamentals, presenting extreme volatility and downside. Portfolio-level pattern: Cluster of insolvencies highlights biotech funding winter, with no capital allocation (dividends/buybacks), insider activity, or forward guidance beyond liquidation warnings.

2 high priority 2 total filings
Β· daily

US Corporate Board Director Changes SEC Filings β€” March 31, 2026

Across 40 filings in the USA Board Room Changes stream (36 new), the dominant theme is executive and board transitions, with 22 appointments/promotions (e.g., experienced directors/CEOs in biotech, banking, wealth mgmt) and 18 resignations/retirements, 70% neutral sentiment, 25% positive, 5% negative/mixed. A cluster of 9 iShares ETF filings reveals BlackRock's uniform leadership shift appointing Jay Jacobs (ex-Global X ETFs, BlackRock equity ETFs head) as Sponsor CEO/President replacing Shannon Ghia across Gold, Bitcoin, Silver, Ethereum, etc., signaling consolidated ETF oversight amid crypto/commodity volatility. Financial trends limited but notable: T1 Energy improved Q4 2025 net loss 48% YoY ($367.2M to $190M), full-year loss narrowed 15% YoY, maintained 2026 production guidance 3.1-4.2 GW with $375-450M EBITDA run-rate 2027. Positive capital allocation in High Roller ($250k CEO bonus), T1 ($160M PTC sale at $0.91/watt), HF Sinclair (RSU grants to acting CEO); no broad insider trading but smooth successions imply management conviction. Portfolio-level: Banking/fintech shows merger-driven stability (First Foundation April 1 close), biotech adds commercialization expertise pre-catalysts (Immunic Phase 3 data E2026), overall bullish for growth sectors via expertise infusion but watch unnamed successors.

40 high priority 40 total filings
Β· daily

US Merger & Acquisition SEC Filings β€” March 31, 2026

Across 10 US SEC filings focused on M&A and takeover activity in the period ending March 31, 2026, a surge in deal completions dominates, including 4 de-SPAC mergers/IPOs/amendments (Trailblazer/Cyabra, Soulpower, Spartacus, Inflection Point, Live Oak), 3 acquisitions (SCYNEXIS, Spire, Oramed/Lifeward), 2 divestitures (BrightSpring, Oramed), and 1 share authorization (Mobivity), signaling robust M&A momentum in biotech, utilities, health services, and SPACs. No explicit period-over-period financial declines reported; instead, themes of portfolio optimization via divestitures and bolt-on acquisitions highlight strategic refocusing without margin compression or YoY revenue drops noted. SPAC activity is particularly hot with 5 filings, pro forma valuations up to $8.5B (Soulpower), and trading commencements imminent. Positive sentiment prevails in 7/10 filings (avg materiality 8.5/10), with forward-looking catalysts like Phase 2 trials (SCYNEXIS Q4 2026) and EPS growth targets (Spire 5-7%). Mixed/neutral tones in Soulpower (closing delay), Live Oak, and Mobivity flag execution risks. Implications: Investors should prioritize post-deal liquidity events and pipeline readouts for alpha, as capital allocation favors growth via M&A over buybacks/dividends.

10 high priority 10 total filings
Β· monthly

US Pre-Market SEC Filings Roundup β€” March 31, 2026

Across 50 overnight SEC filings, mixed sentiment dominates with 14 mixed, 9 positive, 5 negative, and 22 neutral, reflecting resilient capital allocation amid uneven operational trends; energy firms like AleAnna and Dawson show strong YoY EBITDA growth (AleAnna $6.6M FY, Dawson +139% to $4.7M) offset by renewable losses and flat margins, while biotechs (Aktis, DiaMedica, OS Therapies) report clinical progress but widening net losses (OS +224% to $28.8M). Financials and REITs emphasize shareholder returns via buybacks (First Northern 6% of shares ~$15.6M, News Corp $1B program) and dividends (SmartStop $1.60 annualized, AGL $0.60/share), alongside credit expansions (Prologis global facility, Ares 3-year term loan). M&A activity surges in defense/tech (Red Cat $25M Quaze + Apium acquisitions) and resources (Range Impact coal mines boosting assets 20x to $123M), but SPACs and crypto (Solana $40.9M FY loss despite $325M Q4 net income) highlight volatility. Portfolio-level trends include 7/15 reporting entities with revenue growth >20% YoY (e.g., Dawson Q4 +67%), but 6/12 with margin stability or compression; activist push at Lululemon (8.6% stake, proxy fight) signals governance risks. Key implications: Favor buyback-heavy financials and acquisition-driven small caps pre-market, monitor biotech catalysts into mid-2026.

33 high priority 17 medium 50 total filings
Β· daily

Significant Contract Modifications ($10M+) β€” March 30, 2026

Publicis Groupe S.A. gains a stable $373.9M revenue stream via subsidiary Plowshare Group from CDC's National Tobacco Education Campaign, with $275.5M already outlayed and $123.9M in unexercised options through 2026-03-30. This Time & Materials award underscores reliable U.S. government demand in health advertising. Monitor remaining $98.4M obligated spend and post-2026 follow-ons for upside amid funding risks.

1 total filings
Β· daily

Contract Deobligations Alert β€” March 30, 2026

Publicis Groupe S.A. gains stable revenue visibility from a $374M CDC National Tobacco Education Campaign contract via subsidiary Plowshare Group, with $275M already outlayed and performance through March 30, 2026. Upside from $124M unexercised options could boost financials further. Risks include uncertainty on remaining $98M obligated spend and Time & Materials audit exposure, warranting monitoring of outlays and renewals.

1 total filings
Β· daily

High-Value Federal Grants ($5M+) β€” March 30, 2026

Publicis Groupe S.A. gains a stable $373.9M revenue stream via subsidiary Plowshare Group from a CDC tobacco education contract ending March 30, 2026, with $275.5M already outlayed signaling execution reliability. Unexercised options worth $123.9M offer upside, but fiscal uncertainties loom near term-end. This underscores persistent federal commitment to public health advertising amid potential budget pressures.

1 total filings
Β· daily

General Federal Contracts β€” March 30, 2026

Publicis Groupe S.A. gains a stable $374M revenue stream through subsidiary Plowshare Group from a CDC National Tobacco Education Campaign contract ending March 30, 2026, with $275M already outlaid representing 74% of obligated value. This Time & Materials award under full competition underscores reliable U.S. government demand for advertising services. Investors should monitor unexercised $124M options and post-2026 renewal potential amid funding and audit risks.

1 total filings
Β· daily

S&P 500 Technology Sector SEC Filings β€” March 30, 2026

Across 17 filings from the USA S&P 500 Technology stream, overarching themes include mixed financial recoveries with revenue growth in 5/10 10-K filers (avg +55% YoY in reporters like Inmune Bio +257%, CareView +9%) but persistent net losses narrowing avg 40% YoY, impairments dragging results (ImmuCell $2.7M, Inmune $16.5M), and Nasdaq compliance risks in biotech-adjacent plays. Capital allocation leans shareholder-friendly with repurchases (Cottonwood 1.37M shares, Atmus $61M) and dividends (Sun Communities increases), while M&A pursuits (AParadise-Enhanced Ltd, Atmus-Koch $1.5B) signal growth ambitions amid activist pressures (Weave). Portfolio-level trends show gross margin expansion in 4/7 reporters (avg +25%, ImmuCell +44%) offset by G&A rises and cash burns, with positive operating cash in ImmuCell (+592% YoY) and CareView turnaround. Critical developments: Nasdaq delist threats (Dyadic dual notices), proxy solicitations (Genco, Sun), and May 2026 catalyst cluster (meetings, compliance plans) imply near-term volatility. Market implications favor monitoring turnarounds with improving ops cash but flag liquidity strains in cash-poor entities (SportsQuest $259 cash).

13 high priority 4 medium 17 total filings
Β· daily

Nasdaq 100 Stocks SEC Filings β€” March 30, 2026

Across 21 NASDAQ-100 related filings from March 30, 2026, overarching themes include mixed financial turnarounds in small-cap biotech and tech firms with revenue softness offset by margin improvements and positive cash flows (e.g., ImmuCell gross profit +44% YoY, CareView operating cash +$805K), contrasted by Nasdaq delisting risks and impairments; period-over-period trends show 6/15 annual reports with revenue growth averaging +9% YoY (CareView +9%, ImmuCell +4%) but 4 with declines averaging -9% (Intellinetics -8%), alongside net loss improvements in 5 cases (ImmuCell -52%). Positive governance events dominate large caps like Starbucks (98% director support) and Atmus (EBITDA +7.3% YoY, $1.5B acquisition), with capital returns via repurchases (Cottonwood 1.37M shares, Atmus $61M) and debt management (Sun $3B paydown). Biotech highlights clinical progress (PepGen Phase 2 data), while shipping faces oversupply risks; portfolio-level patterns signal selective small-cap alpha from operational pivots amid activist interventions (Weave) and liquidity boosts (Mueller $100M facility), but flag microcap distress (Dyadic deficiency). Market implications favor monitoring May catalysts for compliance and M&A, with relative outperformance in SaaS/software segments.

13 high priority 8 medium 21 total filings
Β· daily

S&P 500 Financials Sector SEC Filings β€” March 30, 2026

Across 50 SEC filings from diverse S&P 500-adjacent names (heavy biotech/energy tilt despite Financials stream), overarching themes include prolific equity capital raises exceeding $2.5B (e.g., OnKure $150M, Capstone $112.5M, Aprea $30M) funding pipelines/growth but risking dilution; M&A surge with $30B+ EV (Sysco/Jet ro $29.1B, Boston Sci/Penumbra, Affinity $142.8M); mixed FY2025 results in 25/50 with revenue (12 up avg +60% YoY like CBAK Q4 +132%, Fathom +25%; 13 down avg -20% like Soluna -22%, Socket -20%) and gross margins compressing avg -350bps in decliners (CBAK 9.4% vs 23.7%). Losses narrowed in 10 biotechs (avg -40% YoY, e.g., Unicycive -30%, OneMedNet -72%) via R&D cuts but widened in 8 (avg +50%). Forward catalysts cluster in May-Jun 2026 (merger votes, AGMs, PDUFA); capital allocation favors reinvestment over returns (Conoco $9B buybacks/divs outlier). Implications: alpha in accretive M&A/biotech catalysts, caution on dilution/margin squeezes; portfolio trend toward defensive M&A plays amid volatile growth.

27 high priority 23 medium 50 total filings
Β· daily

S&P 500 Consumer Staples Sector SEC Filings β€” March 30, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Staples intelligence stream (despite diverse tickers including biotechs, energy, and SPACs), mixed sentiment dominates (14/50 mixed), with revenue declines averaging ~10% YoY in 18 reporting companies (e.g., ARKO -12.3%, Intellinetics -8%, Sangamo -32%), offset by cost reductions narrowing net losses in 9/22 loss-reporting firms (e.g., Neumora -3% FY loss, ImmuCell -52%). Biotech/pharma filings (10+) highlight pipeline catalysts clustered in Q2-H2 2026, while energy/utilities show debt optimizations (Atmos extensions, Electra liabilities -44-99%). Capital allocation leans conservative with sparse dividends (ARKO $0.26/share, Brookfield $0.07/share) and no buybacks noted; cash runway extensions into 2027 common amid high burn. Portfolio-level trends reveal margin expansion in 7/15 (e.g., ImmuCell +44% gross profit) despite volume pressures, signaling operational resilience but macro headwinds. M&A/divestitures active (CVD SDC sale $16.9M Q2 2026 close, KEEMO control change), with AGMs/earnings imminent. Implications: Selective opportunities in catalysts and turnarounds, caution on cash burns and rev softness.

31 high priority 19 medium 50 total filings
Β· daily

S&P 500 Industrials Sector SEC Filings β€” March 30, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (including adjacents like energy and materials), FY2025 results reveal mixed performance with standout revenue accelerations in niche growth areas (e.g., CBAK Energy Q4 +131.8% YoY to $58.8M driven by LEV +524%, Legence +21.5% to $2.55B fueled by data centers +50.1%) offset by widespread margin compressions (e.g., CBAK FY gross margin -1430bps to 9.4%) and net losses (12/20 10-Ks reported wider losses YoY). Refinancings strengthened balance sheets (Ingevity $750M rev facility, MediaAlpha $150M term loan), while M&A activity (Addentax 62% stake in Keemo Fashion, Hecla Quebec sale) and capital returns ($9B ConocoPhillips buybacks/dividends) signal confidence. Proxies (Baker Hughes, Conoco, S&T Bancorp) show low insider ownership (<1%) and standard governance with ownership guideline hikes. Forward catalysts include mid-2026 clinical readouts (Reviva Phase 3, Connect Biopharma Phase 2), April-May shareholder meetings, and AAN poster (AEON April 2026). Portfolio implications: Bullish on data/energy efficiency plays amid margin pressures; monitor going concern risks in biotechs (Reviva, Genprex, CISO). Actionable now: Favor refinanced industrials over loss-makers.

28 high priority 22 medium 50 total filings
Β· daily

S&P 500 Energy Sector SEC Filings β€” March 30, 2026

The S&P 500 Energy stream reveals proxy season kicking off with 10+ AGMs clustered in May 2026, highlighting strong 2025 performance at key players like ConocoPhillips (2,375 MBOED production, $19.8B cash ops, $9B shareholder returns including $5B buybacks/$4B dividends, 15% YoY Lower 48 drilling efficiency gains, $1B Marathon synergies). Devon Energy's proposed Q2 2026 merger with Coterra (mixed sentiment due to risks/no appraisal rights) signals consolidation amid neutral-to-positive sentiment overall. Portfolio-level trends show robust capital returns and operational efficiencies in upstream (COP) contrasting neutral governance disclosures elsewhere; COPT Defense (non-core but contextual) boasts 95% leased rates and exceeded 2025 scorecard (except one metric). No widespread margin compression or declines noted, with forward catalysts centered on virtual AGMs (May 12-21) and merger close. Baker Hughes discloses low insider ownership (<1%) and strict no-pledge policies. Mixed signals from non-energy filings (e.g., AParadise unproven DTC platform, Neogen exec departure) underscore energy focus purity but highlight M&A risks.

7 high priority 5 medium 12 total filings
Β· daily

US Material Events SEC 8-K Filings β€” March 30, 2026

Across 50 8-K filings from March 30, 2026, the dominant theme is aggressive capital structure optimization through refinancings, new credit facilities, and note issuances (e.g., Ingevity's $750M revolver, Nexstar's $1.75B Term B-7, MediaAlpha's $150M term/$60M rev), enhancing liquidity without reported performance declines. Strategic M&A and divestitures highlight focus on core operations (Leidos $2.4B ENTRUST acquisition doubling energy exposure; Spire $215M gas marketing sale; Compass $292.5M Sterno divestiture reducing leverage below 1.0x). Biotech sector shows robust funding and milestones (OnKure $150M raise for PI3KΞ± inhibitors with H1 2027 INDs; Connect Biopharma positive Phase 1 FEV1 improvements ~200-400mL, Phase 2 mid-2026; Aprea $30M for ACESOT-1051 expansion to Q1 2028 runway). Limited period-over-period data reveals mixed guidance (Spire affirms FY2026 $5.25–$5.45 EPS but cuts FY2027 to $5.40–$5.60 from $5.65–$5.85); Inogen reaffirms Q1/FY2026 outlook post positive EBITDA turn. Board changes are prevalent (50% of filings), mostly neutral appointments/resignations, with rare discord (Ensysce director exit over severance). No broad insider trading patterns, but capital allocation leans toward deleveraging and growth reinvestment over dividends/buybacks. Overall, positive sentiment in 40% of filings signals resilience, with opportunities in energy/utilities and biotech amid neutral/mixed financing dilution risks.

50 high priority 50 total filings